Jul 31 |
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
|
Jul 30 |
Biogen, Eisai present positive three-year use data for Leqembi
|
Jul 30 |
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC)...
|
Jul 30 |
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
|
Jul 30 |
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
Jul 30 |
Countdown to Biogen (BIIB) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
|
Jul 30 |
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
|
Jul 29 |
EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Leqembi
|
Jul 29 |
Alzheimer’s Disease: Some trials to watch over the next year
|
Jul 29 |
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
|